You are here
IMMUNOMEDICS, INC.
UEI: S4NHH3294XM6
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Novel Antithrombotic Diadenosine Tetraphosphate Analogs
Amount: $213,982.00DESCRIPTION (provided by applicant): The overall goal of this SBIR application is to initiate a clinical trial with a bispecific antibody (bsMAb) pretargeting procedure for detecting pancreatic carci ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
CBT Supervisor's Toolkit: Phase II
Amount: $200,782.00DESCRIPTION (provided by applicant): Triple-negative breast cancer (TNBC) is a subset of breast cancers with poor prognosis and high mortality due to the lack of effective therapeutic regimens. This P ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Combined radio- and immunotherapy of aggressive NHL
Amount: $1,137,221.00DESCRIPTION (provided by applicant): The main goal of this Phase I/II SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherapy ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Bispecific antibody pretargeted immunoPET of prostate cancer
Amount: $276,833.00DESCRIPTION (provided by applicant): This Phase I application is being submitted with the main objective to develop a highly sensitive and specific imaging method for prostate cancer that is based on ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Humanized Anti-Trop2-SN-38 Conjugate For Advanced Pancreatic Cancer
Amount: $227,025.00DESCRIPTION (provided by applicant): The main objective of this Phase I SBIR application is to perform the first-in-man studies with a new antibody-drug conjugate (ADC) composed of a humanized antibo ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Use of milatuzumab in modulating graft vs. host disease
Amount: $191,143.00DESCRIPTION (provided by applicant): Control of GVHD by milatuzumab in hu-SCID mice Dendritic cells (DCs) are the primary initiator of graft-versus-host disease (GVHD), a major and life- threatening c ...
STTRPhase I2011Department of Health and Human Services National Institutes of Health -
Development of an interferon-alpha-veltuzumab conjugate for CD20-targeted therapy
Amount: $2,828,870.00DESCRIPTION (provided by applicant): As a continuation of a successful Phase I SBIR, this Phase II application is directed towards the further development of a novel immunocytokine, named 20-2b, for i ...
SBIRPhase II2010Department of Health and Human Services National Institutes of Health -
Novel multivalent/multifunctional agents derived from a humanized anti-insulin-li
Amount: $192,688.00DESCRIPTION (provided by applicant): Cancer of the kidney and renal pelvis killed approximately 13,010 men and women in the United States last year. One of the most challenging forms of this type of c ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
F-18 Labeled Peptides for Pretargeted PET Imaging of Pancreatic Cancer
Amount: $1,122,960.00DESCRIPTION (provided by applicant): Our primary interest is to develop an imaging method based on bispecific antibody (bsMAb) pretargeting used in combination with F-18 labeled peptides. Such a metho ...
SBIRPhase II2009Department of Health and Human Services National Institutes of Health -
Combined radio- and immunotherapy of aggressive NHL
Amount: $859,792.00DESCRIPTION (provided by applicant): The main goal of this Phase I/II SBIR application is to translate rapidly preclinical findings that show the advantage of using a combination radioimmunotherap ...
SBIRPhase I2009Department of Health and Human Services National Institutes of Health